Abstract:Among the best-established causal risk factors for cardiovascular disease is the blood concentration of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), an antagonist to the LDL receptor, has emerged as a promising therapeutic target for the prevention of coronary heart disease. Current PCSK9 inhibitors are administered via subcutaneous injection, and their effects are short-lived. An alternative “one-and-done” strategy using genome editing to disrupt PCSK9 at the DNA level has been demonstrated in preclinical animal models, including non-human primates. However, concerns about the permanence and irreversibility of the genomic changes have been raised and might limit the acceptance of the therapies. Recently, a set of CRISPR-based epigenome editing tools, CRISPRoff and CRISPRon, were reported to regulate gene expression via site-directed methylation and demethylation of gene promoters, respectively. We hypothesized that these epigenome editing tools could durably and reversibly induce methylation changes in the PCSK9 promoter and thereby modulate its expression. We first screened CRISPRoff guide RNAs (gRNAs) targeting the PCSK9 promoter, individually and in dual combinations, for their ability to reduce PCSK9 expression in the human HuH-7 hepatoma cell line. We then performed long-term experiments with the lead candidate gRNAs. We found that these CRISPRoff gRNAs induced profound increases in methylation at CpG dinucleotides in the PCSK9 promoter, with up to 80% decreases in PCSK9 expression. These methylation increases and gene expression decreases have endured through >56 cell divisions so far, with only mild attenuation over time. Using the same gRNAs with CRISPRon in cells previously treated with CRISPRoff, we observed moderate decreases in methylation and increases in PCSK9 expression. Having established these effects in vitro , we are similarly assessing the durability and reversibility of epigenome editing using the lead gRNAs in a PCSK9 -humanized mouse model. Overall, this work provides a proof of concept of precise gene regulation via methylation and demethylation and suggests a potential new therapeutic approach for protection against coronary heart disease.

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9

Abstract 125: Reversible Epigenome Editing Of PCSK9 As A Therapeutic Strategy

Abstract 27: Therapeutic Targeting of Human Lipid Genes With in vivo CRISPR-Cas9 Genome Editing

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

Extracellular vesicle‐mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin‐kexin type 9 (Pcsk9) in primary mouse hepatocytes

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders

Triple‐Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases

PCSK9 Inhibition-Based Therapeutic Approaches: an Immunotherapy Perspective.

PCSK9 Inhibition: From Current Advances to Evolving Future

Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9

Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia

Abstract 419: Therapeutic Potential Of The Proprotein Convertase Subtilisin/Kexin (PCSK) Family In Vascular Disease